Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet's disease.

Literature DB >> 17063282

Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet's disease.

N Melillo¹, S Sangle, M R Stanford, T C Andrews, D P D'Cruz.

Abstract

Behçet's disease (BD) is a chronic relapsing-remitting inflammatory disorder of unknown origin, affecting multiple organs. Neurological involvement is one of the most devastating manifestations of BD and may be fatal. We report a 36-year-old woman with neuro-Behçet who was treated with low-dose pulse cyclophosphamide (St. Thomas' protocol) and methylprednisolone, with almost complete clinical remission.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2006 PMID： 17063282 DOI： 10.1007/s10067-006-0385-0

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

13 in total

1. Linkage mapping of a novel susceptibility locus for Behçet's disease to chromosome 6p22-23.

Authors: A Gül; A H Hajeer; J Worthington; W E Ollier; A J Silman
Journal: Arthritis Rheum Date: 2001-11

2. Prevalence and patterns of neurological involvement in Behcet's disease: a prospective study from Iraq.

Authors: A Al-Araji; K Sharquie; Z Al-Rawi
Journal: J Neurol Neurosurg Psychiatry Date: 2003-05 Impact factor: 10.154

3. On the use of neuropsychology to diagnose brain damage and study brain-behavior relationships: a comment on Luria.

Authors: Daniel Tranel
Journal: Cortex Date: 2005-04 Impact factor: 4.027

Review 4. New approaches in the treatment of Adamantiades-Behçet's disease.

Authors: Nicolò Pipitone; Ignazio Olivieri; Fabrizio Cantini; Giovanni Triolo; Carlo Salvarani
Journal: Curr Opin Rheumatol Date: 2006-01 Impact factor: 5.006

5. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.

Authors: Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal: Arthritis Rheum Date: 2004-12

6. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.

Authors: I Martin-Suarez; D D'Cruz; M Mansoor; A P Fernandes; M A Khamashta; G R Hughes
Journal: Ann Rheum Dis Date: 1997-08 Impact factor: 19.103

7. Evaluation of diagnostic ('classification') criteria in Behçet's disease--towards internationally agreed criteria. The International Study Group for Behçet's disease.

Authors:
Journal: Br J Rheumatol Date: 1992-05

8. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors: G Akman-Demir; P Serdaroglu; B Tasçi
Journal: Brain Date: 1999-11 Impact factor: 13.501

9. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.

Authors: D T Boumpas; H A Austin; E M Vaughan; C H Yarboro; J H Klippel; J E Balow
Journal: Ann Intern Med Date: 1993-09-01 Impact factor: 25.391